Navigation Links
Isis Initiates Phase 1 Study of ISIS-PTP1BRx to Treat Type 2 Diabetes
Date:7/21/2011

CARLSBAD, Calif., July 21, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated a Phase 1 clinical study for ISIS-PTP1BRx, an antisense drug for the treatment of type 2 diabetes targeting protein tyrosine phosphatase-1B, PTP-1B.  ISIS-PTP1BRx is designed to increase the body's sensitivity to the natural hormone insulin, resulting in better glucose control for patients with type 2 diabetes.  Because of its unique mechanism ISIS-PTP1BRx has the potential to contribute to the treatment of type 2 diabetes without causing weight gain or hypoglycemia.  The reductions in LDL-C produced by PTP-1B inhibition should also provide an added benefit to patients.

"We are developing ISIS-PTP1BRx for patients whose glucose is inadequately controlled by insulin or oral therapies.  Having demonstrated the attractive profile of a PTP-1B inhibitor with ISIS 113715, we are now proceeding with the development of a more potent PTP-1B inhibitor," said Sanjay Bhanot, M.D., Ph.D., Vice President of Metabolic Disorders and Translational Medicine at Isis.  "We believe that ISIS-PTP1BRx could be a safer insulin sensitizer.  The only class of insulin sensitizers currently available also broadly affects the transcription of multiple genes, which leads to side effects.  Some of these side effects, such as increases in LDL-C, weight gain, and thinning of bones are particularly problematic in diabetics.  Because ISIS-PTP1BRx selectively reduces only the PTP-1B protein, a mechanism distinct from current insulin sensitizers, it is unlikely to have those side effects."

Earlier Phase 2 studies of ISIS 113715 provided evidence of the therapeutic potential of inhibiting PTP-1B.  In those studies, PTP-1B inhibition improved glucose control and reduced LDL-C in both newly diagnosed diabetic patients and in patients who
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
2. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
6. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
7. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. Prolexys Pharmaceuticals Initiates Phase 1 Study
10. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
11. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... Calif. , May 5, 2015 ... biopharmaceutical company focused on cardio-renal, gastrointestinal, and metabolic ... clinical trial evaluating tenapanor in Stage 3 chronic ... and albuminuria did not meet the primary endpoint ... patients compared to patients receiving placebo. ...
(Date:5/5/2015)... , May 5, 2015 North ... $94.9 million in 2014, and is estimated to grow ... 7.8% from 2014 to 2019. Browse through ... Market for an analysis of industry trends and segments, ... http://www.micromarketmonitor.com/market/north-america-glaucoma-surgery-devices-8830146604.html Early buyers ...
(Date:5/5/2015)... Valley Medical Center, named a Top 100 Hospitals® in the ... to deploy the wireless Leaf Patient Monitoring System in its ... labor and risk of caesarian births. Studies show ... is reduced in mothers who are upright and mobile during ... epidurals and tend to lie in their labor room beds. ...
Breaking Medicine Technology:Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 2Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 3Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 4Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 5Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 6North America Ophthalmology Glaucoma Surgery Device Market is Expected to Reach $138.3 Million by 2019, at a CAGR of 7.8% From 2014 to 2019 2North America Ophthalmology Glaucoma Surgery Device Market is Expected to Reach $138.3 Million by 2019, at a CAGR of 7.8% From 2014 to 2019 3Desert Valley Medical Center First to Use Leaf Patient-Wearable Technology to Help Reduce C-Sections, Speed Labor 2Desert Valley Medical Center First to Use Leaf Patient-Wearable Technology to Help Reduce C-Sections, Speed Labor 3Desert Valley Medical Center First to Use Leaf Patient-Wearable Technology to Help Reduce C-Sections, Speed Labor 4
... , RYE, N.Y. , July 28 Curemark, ... on the treatment of neurological diseases, announced that Saint Peter,s University Hospital ... Phase III clinical trials for CM-AT , Curemark,s autism treatment.   ... Saint Peter,s is affiliated ...
... SEATTLE , July 28 HemaQuest Pharmaceuticals, ... for sickle cell disease, beta thalassemia and EBV-related cancers, ... to its Series B financing by new investor, ... B financing to $16M . The financing is ...
Cached Medicine Technology:Curemark Opens Autism Trials at New Jersey Site 2Curemark Opens Autism Trials at New Jersey Site 3HemaQuest Pharmaceuticals Raises Additional $4M to Bring Total to $16M in Series B Financing 2
(Date:5/5/2015)... 2015 Horizon Blue Cross Blue Shield ... secure credit rating of “A” from Standard & Poor’s. ... week, the Wall Street ratings agency cited the company’s ... in determining the rating and “stable” outlook. , “Providing ... our top priorities, so we are pleased to have ...
(Date:5/5/2015)... PA (PRWEB) May 05, 2015 The 2015 ... raised $110,000 to benefit their global research, outreach and patient ... silent auction, and awards ceremony that attracted hundreds of supporters. ... of the discovery of the hepatitis B virus (HBV) by ... Blumberg received the Nobel Prize in Medicine for his discovery ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 The newly minted Regan ... experiences of Dr. Brad Reedy from his 20 years ... was asked why she chose to publish a parenting book and ... parent (and publisher) is the idea that it is a journey, ... our children are on the trek sometimes together and sometimes not...that ...
(Date:5/5/2015)... 05, 2015 Nutritional science and medical ... a variety of health conditions and illnesses linked to ... to adopt clean eating methods to rid the body ... with over-consumption of fast and processed foods. Patients find ... to follow and report feeling better and losing excess ...
(Date:5/5/2015)... 2015 This year, PolyU researchers garnered ... Merit Awards, three Gold Medals and four Silver Medals ... as follows: , (1) Grand Prize and Gold Medal ... Fashion Design and Fitting, Principal Investigator: Dr Allan Chee-kooi ... industry relies very much on the “mannequin” for many ...
Breaking Medicine News(10 mins):Health News:Horizon Blue Cross Blue Shield of New Jersey Maintains “A” Credit Rating from Standard & Poor’s 2Health News:Hepatitis B Foundation Marks 50th Anniversary of HBV Discovery at its Crystal Ball Gala 2Health News:Hepatitis B Foundation Marks 50th Anniversary of HBV Discovery at its Crystal Ball Gala 3Health News:The Last Parenting Book You Will Ever Need: Veteran Publisher Judith Regan Releases A Provocative New Book By Dr. Brad Reedy, "The Journey Of The Heroic Parent" 2Health News:The Last Parenting Book You Will Ever Need: Veteran Publisher Judith Regan Releases A Provocative New Book By Dr. Brad Reedy, "The Journey Of The Heroic Parent" 3Health News:Diet Doc Introduces Diet Plans that Teach Patients how to Eat Clean by Getting Back to Basics and Exchanging Processed Foods for Clean, Nutritious Foods 2Health News:Diet Doc Introduces Diet Plans that Teach Patients how to Eat Clean by Getting Back to Basics and Exchanging Processed Foods for Clean, Nutritious Foods 3Health News:PolyU wins top prizes in Geneva’s Invention Expo 2Health News:PolyU wins top prizes in Geneva’s Invention Expo 3Health News:PolyU wins top prizes in Geneva’s Invention Expo 4Health News:PolyU wins top prizes in Geneva’s Invention Expo 5
... Neurological Testing Firm Unveils Findings, Drawn Directly From ... Consumer ConfidenceBERKELEY, Calif., Feb. 23 As one ... NeuroFocus, the world,s leading neurological testing company, put ... how those firms can help their battered brands ...
... Services announces the renewal of its Chemistry Services Agreement with ... continue to provide chemistry services in support of Boehringer,s pharmaceutical ... ... Canada (PRWEB) February 23, 2009 -- Dalton Pharma Services announces ...
... the most cutting edge drug and alcohol detox centers in the United ... Health is able to offer a comprehensive program that treats the root ... methods. , ... Fort Collins, CO (PRWEB) February 23, 2009 -- ...
... HEIDELBERG, Germany, Feb. 23 Anatomist Dr. Gunther von Hagens ... anatomical exhibitions that bear his name - issued a clarification ... reports that confused a cadaver display announced in Paris, with ... von Hagens said, "I have been an anatomist for more ...
... lifespan is limited by telomeres, DNA sequences that cap ... may be copied. A new study reported in ... describes how telomere dysfunction in skin cells can lead ... from Spain investigated the molecular mechanisms underlying skin cell ...
... be about an intervention and the growing problem of ... of compulsive gamblers were women, today that figure is ... VA) specializes in treating compulsive gambling, is licensed to ... treatment centers in the US), encourages women gamblers with ...
Cached Medicine News:Health News:Billions for Bank Bailouts, But How to Rebuild the Brands? NeuroFocus Reveals New Brainwave-Based Solutions 2Health News:Billions for Bank Bailouts, But How to Rebuild the Brands? NeuroFocus Reveals New Brainwave-Based Solutions 3Health News:Dalton Pharma Services and Boehringer Ingelheim (Canada) Ltd. Announce the Renewal of their Chemistry Services Agreement 2Health News:Tri-Life Health Offers NTR Addiction Recovery Center in Fort Collins, CO 2Health News:Tri-Life Health Offers NTR Addiction Recovery Center in Fort Collins, CO 3Health News:Anatomist Dr. Gunther von Hagens, Pioneer of Anatomical Exhibitions Not Affiliated With Copycat Display in Paris 2Health News:The first Intervention About Women Compulsive Gamblers Airs on A&E February 23, 2009 at 9 PM: Williamsville Wellness will be Featured 2
... The Techne TC-312 Thermal Cycler is ... market. Features & Benefits include: ... networking, Alpha-numeric screen, keypad and program naming, ... numerous applications in Molecular Biology and Diagnostic ...
PTC-100 cycler with Hot Bonnet heated lid,holds sixty 0.5ml tubes...
... 0.2ml sub-ambient block and automatic height adjusting ... up to 3C/second; Accurate block performance; Absolute ... than 0.5C within 15 seconds; Oil free ... storage of up to 60 programs; 0.2 ...
... The RapidCycler is the first instrument ... reactions. The instrument's rapid temperature cycling system ... air to samples contained in microcapillary tubes ... cooling the samples with blasts of high ...
Medicine Products: